Michael Caplan, MD
Ophthalmology · Houston, TXNPI 1225034549
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alcon accounts for 75.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $4,816 and has fallen 87.3% since, to $613 in 2025.
Across 91 payments — averaging $102.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$7K
- AbbVie$391
- Johnson & Johnson Surgical Vision, Inc.$388
- Glaukos Corporation$318
- Carl Zeiss Meditec USA, Inc.$317
- Carl Zeiss Meditec, Inc.$207
- plus $695 from 12 others
Across 505 payments — averaging $2797.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$934K
- Alcon Research LLC$475K
- Glaukos Corporation$4K
What the payments were for
- Consulting fees$4,72551%
- Speaking & faculty fees$390%
- Travel & lodging$7068%
- Food & beverage$3,84841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 29 | $7,003 |
| AbbVie(2 entities) | 18 | $391 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $388 |
| Glaukos Corporation | 2 | $318 |
| Carl Zeiss Meditec USA, Inc. | 5 | $317 |
| Carl Zeiss Meditec, Inc. | 3 | $207 |
| Rxsight Inc | 3 | $185 |
| Bausch & Lomb Americas Inc. | 3 | $183 |
| Sun Pharmaceutical Industries Inc. | 3 | $63 |
| Oyster Point Pharma, Inc. | 2 | $46 |
| Biotissue Holdings Inc. | 2 | $44 |
| Novartis | 3 | $42 |
| Tarsus Pharmaceuticals, Inc. | 1 | $31 |
| Dompe US, Inc. | 1 | $31 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| Eyepoint US, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$3,521
- AcrySof UltraSert$175
- Clareon PanOptix Pro$149
- iDose$148
- Unity$147
- IC-8 Apthera IOL$147
- IDESIGN RS$136
- AcrySof IQ PanOptix UV IOL$132
- AcrySof IQ VIVITY$132
- RXSIGHT CONTACT LENS$129
- RXSIGHT INJECTOR CARTRIDGE$129
- RXSIGHT INJECTOR HANDPIECE$129
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$129
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$129
- VisuMax$123
- ARTEVO 800$123
How this compares
$9,318 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 83 | $43,053 |
| Bromfenac Sodium | 297 | $35,721 |
| Prednisolone Acetate | 1,015 | $34,622 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $16,021 |
| XiidraLifitegrast | 15 | $14,166 |
| RestasisCyclosporine | 12 | $13,915 |
| Ketorolac Tromethamine | 631 | $12,456 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 53 | $8,614 |
| Ciprofloxacin Hcl | 807 | $7,963 |
| Latanoprost | 444 | $6,282 |
| Brimonidine Tartrate | 80 | $4,327 |
| Travoprost | 21 | $4,199 |
| Brinzolamide | 13 | $3,784 |
| MoxifloxacinMoxifloxacin Hcl | 96 | $2,505 |
| Loteprednol Etabonate | 12 | $1,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $391 | $72,988130 claims |
| Bausch & Lomb Americas Inc.Xiidra | $183 | $14,16615 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $21 | $1,72112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.